INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Skelton Laurence Matthew reported VERA

Chief Commercial Officer · Vera Therapeutics, Inc. · Class A Common Stock

Side
A
Value
—
Shares
20.0K
Price
—
Executed
Feb 4, 2026
Disclosed
Feb 6, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 4 executedFeb 6, 2026 disclosed

VERA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 43.7% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · VERA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    8
    FM
    Fordyce MarshallDirector, PRESIDENT AND CEO
    VERAVera Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$685K
    18.5K sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    0
    FM
    Fordyce MarshallDirector, PRESIDENT AND CEO
    VERAVera Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$54K
    18.5K sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    0
    FM
    Fordyce MarshallDirector, PRESIDENT AND CEO
    VERAVera Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    18.5K sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    13
    YR
    Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR
    VERAVera Therapeutics, Inc.
    Option exercise
    		M—
    5,000 sh
    		Sep 11, 2026Sep 14, 2026
    traded Sep 11, 2026
    		+3dSEC FORM 4

    Evidence

    13
    YR
    Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR
    VERAVera Therapeutics, Inc.
    Option exercise
    		M$20K
    5,000 sh
    		Sep 11, 2026Sep 14, 2026
    traded Sep 11, 2026
    		+3dSEC FORM 4

    Evidence

    0
    FM
    Fordyce MarshallDirector, PRESIDENT AND CEO
    VERAVera Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    18.5K sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    FM
    Fordyce MarshallDirector, PRESIDENT AND CEO
    VERAVera Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$54K
    18.5K sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    8
    FM
    Fordyce MarshallDirector, PRESIDENT AND CEO
    VERAVera Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$650K
    18.5K sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    1
    FM
    Fordyce MarshallDirector, PRESIDENT AND CEO
    VERAVera Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$3,382
    88 sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    11
    FM
    Fordyce MarshallDirector, PRESIDENT AND CEO
    VERAVera Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$698K
    18.4K sh
    		Jun 23, 2026Jun 24, 2026
    traded Jun 23, 2026
    		+1dSEC FORM 4

    Evidence

    15
    HK
    Hall KimballDirector
    VERAVera Therapeutics, Inc.
    Grant or award
    		A—
    17.1K sh
    		May 21, 2026May 26, 2026
    traded May 21, 2026
    		+5dSEC FORM 4

    Evidence

    4
    FM
    Fordyce MarshallDirector, PRESIDENT AND CEO
    VERAVera Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$159K
    4,281 sh
    		May 12, 2026May 13, 2026
    traded May 12, 2026
    		+1dSEC FORM 4

    Evidence

    11
    FM
    Fordyce MarshallDirector, PRESIDENT AND CEO
    VERAVera Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$521K
    14.2K sh
    		May 12, 2026May 13, 2026
    traded May 12, 2026
    		+1dSEC FORM 4

    Evidence

    5
    FM
    Fordyce MarshallDirector, PRESIDENT AND CEO
    VERAVera Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$41K
    900 sh
    		Apr 14, 2026Apr 15, 2026
    traded Apr 14, 2026
    		+1dSEC FORM 4

    Evidence

    15
    FM
    Fordyce MarshallDirector, PRESIDENT AND CEO
    VERAVera Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$617K
    14.1K sh
    		Apr 14, 2026Apr 15, 2026
    traded Apr 14, 2026
    		+1dSEC FORM 4

    Evidence

    11
    FM
    Fordyce MarshallDirector, PRESIDENT AND CEO
    VERAVera Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$353K
    7,921 sh
    		Apr 14, 2026Apr 15, 2026
    traded Apr 14, 2026
    		+1dSEC FORM 4

    Evidence

    9
    WJ
    Wright-Mitchell JaneChief Legal Officer
    VERAVera Therapeutics, Inc.
    Grant or award
    		A—
    56.9K sh
    		Mar 23, 2026Mar 25, 2026
    traded Mar 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    WJ
    Wright-Mitchell JaneChief Legal Officer
    VERAVera Therapeutics, Inc.
    Grant or award
    		A—
    42.4K sh
    		Mar 23, 2026Mar 25, 2026
    traded Mar 23, 2026
    		+2dSEC FORM 4

    Evidence

    29
    BR
    Brenner RobertChief Medical Officer
    VERAVera Therapeutics, Inc.
    Open-market sale
    		SELL$90K
    2,151 sh
    		Feb 23, 2026Feb 25, 2026
    traded Feb 23, 2026
    		+2dSEC FORM 4

    Evidence

    29
    SM
    Skelton Laurence MatthewChief Commercial Officer
    VERAVera Therapeutics, Inc.
    Open-market sale
    		SELL$66K
    1,582 sh
    		Feb 23, 2026Feb 25, 2026
    traded Feb 23, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002108080-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 4, 2026
    Published
    Feb 6, 2026
    Ingested by INSIDER
    Nov 5, 04:18 UTC
    Last re-read
    Nov 5, 04:18 UTC

    Extracted facts

    Filer
    Skelton Laurence Matthew
    Role
    Chief Commercial Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Vera Therapeutics, Inc.
    Ticker
    VERA
    Shares
    20.0K
    Price per share
    $0
    Execution date (reported)
    Feb 4, 2026
    Owned after transaction
    65.8K shares
    Days from execution to publication
    2

    What this establishes

    Skelton Laurence Matthew filed this Form 4 reporting a grant or award of VERA on Feb 4, 2026. It became public on Feb 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Commercial Officer
    Skelton Laurence Matthewcik:0002108080
    Issuer
    Vera Therapeutics, Inc.cik:0001831828

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.